California Gov. Jerry Brown vetoed a state bill that would limit the use of biosimilars by requiring pharmacists to notify doctors and patients if a biosimilar was being substituted for the prescribed drug, which the bill said could be done in cases in which the FDA says the biosimilar is interchangeable with the brand-name drug. A notification requirement was premature because the FDA has yet to decide on the standards for biosimilars' interchangeability with original products, Brown said.

Related Summaries